March S&P 500 E-Mini futures (ESH24) are trending down -0.27% this morning as market participants looked ahead to a new round of U.S. economic data, comments from Fed officials, and earnings reports from...
/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and...
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 213.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases is...
/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...